- Roche (OTCQX:RHHBY +0.6%) unit Genentech will collaborate with privately held Genesis Therapeutics aimed at utilizing artificial intelligence (AI) to enhance drug discovery and development. The partnership will leverage Genesis' graph machine learning and drug discovery know-how to identify candidates across a range of diseases.
- Under the terms of the deal, Genesis will receive an undisclosed upfront payment, milestones and royalties on net sales.
- https://seekingalpha.com/news/3623333-roche-teams-up-genesis-therapeutics-in-ai-driven-drug-discovery
Monday, October 19, 2020
Roche teams up with Genesis Therapeutics in AI-driven drug discovery
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.